Estramustine phosphate sodium

Research use only, not for human use.

Estramustine phosphate sodium is an antimicrotubule chemotherapy agent; arrests prostate cancer cells in the G2/M phase of the cell cycle.

Estramustine phosphate sodium is an antimicrotubule chemotherapy agent; arrests prostate cancer cells in the G2/M phase of the cell cycle.(In Vitro):Estramustine phosphate sodium (1 μg/ mL, 48 h) suppresses PC3 cell growth.Estramustine phosphate sodium (2 μg/mL, 48 h) elevates phosphatidylserine eversion amount on PC3 cells and induces PC3 cell apoptosis through reducing miR-31.Estramustine phosphate sodium (0-40 μM, 24-72 h) inhibits cell proliferation and tubulin cytoskeleton in RAW 264.7 cells.Estramustine phosphate sodium (10 μM, 24 h) inhibits TGF-β-induced RAW 264.7 cell migration, as well as TGF-β-induced uPA production by inhibiting Smad3 activation.(In Vivo):Estramustine phosphate sodium (Intraperitoneal injection, 4 or 12 mg/kg, a daily dose for 2 weeks) inhibits PAC120 tumor growth 53% by day 35.

Estramustine phosphate sodium (1 μg/ mL, 48 h) suppresses PC3 cell growth.Estramustine phosphate sodium (2 μg/mL, 48 h) elevates phosphatidylserine eversion amount on PC3 cells and induces PC3 cell apoptosis through reducing miR-31.Estramustine phosphate sodium (0-40 μM, 24-72 h) inhibits cell proliferation and tubulin cytoskeleton in RAW 264.7 cells.Estramustine phosphate sodium (10 μM, 24 h) inhibits TGF-β-induced RAW 264.7 cell migration, as well as TGF-β-induced uPA production by inhibiting Smad3 activation. Cell Viability Assay Cell Line:PC3 cells Concentration:1 μg/ mL Incubation Time:48 h Result:Suppressed PC3 cell growth.Immunofluorescence Cell Line:RAW 264.7 cells Concentration:10 μM Incubation Time:24 h Result:Disrupted the interphase microtubules.Cell Migration Assay Cell Line:18 h of TGF-β treated RAW 264.7 cells Concentration:10 μM Incubation Time:24 h Result:Inhibited TGF-β-Induced Cell Migration.

Estramustine phosphate sodium (Intraperitoneal injection, 4 or 12 mg/kg, a daily dose for 2 weeks) inhibits PAC120 tumor growth 53% by day 35. Animal Model:Swiss nu/nu (nude) male mice (5-week-old) bearing PAC120 tumors Dosage:4 mg/kg, 12 mg/kg Administration:Intraperitoneal injection; daily; for 2 weeks Result:Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.Animal Model:Human prostate cancer xenograft PAC120Dosage:4 or 12 mg/kg, a daily dose for 2 weeks.Administration:Intraperitoneal injectionResult:Inhibited PAC120 tumor growth 53% by day 35.

——

Apoptosis

Caspase

Microtubule/Tubulin

Cancer

——

52205-73-9

564.35

C23H30Cl2NNa2O6P

>98% (HPLC)

H2O : 62.5 mg/mL 110.75 mM;DMSO : 5 mg/mL 8.86 mM

[Na+].[Na+].ClCCN(CCCl)C(=O)Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OP([O-])([O-])=O)c4cc3

——

(-20℃)

With Ice Pack

≥ 2 years